TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02901860

Intervention type: OTHER
Intervention: Sleep, Dietary and Cardio-metabolic Measurements
Description: At home session: 2-weeks of wrist actigraphy and sleep diaries; a food diary for the three days preceding the lab session; 24-h period of ambulatory blood pressure on a non-work day for participant. Work schedules over a 4-week period will be collected and participants identified as traditional or non-traditional workers.~Subjects will begin the stay in the research unit in the evening and will remain for about 16-20 hr. Saliva samples will be taken every 30 min from admission until bedtime. Bedtime with polysomnography will be from 11:00pm to 7:00am. Questionnaires will be administered; height, weight and waist/hip circumference and bioimpedance measurement; standard 3-h oral glucose tolerance test and blood tests (CBC, electrolytes, renal, liver and thyroid function , hemoglobin A1c, SHBG levels). For individuals with diabetes only fasting blood samples will be taken.

Intervention type: OTHER
Intervention: Sleep, Dietary and Cardio-metabolic Measurements
Description: At home session: 2-weeks of wrist actigraphy and sleep diaries; a food diary for the three days preceding the lab session; 24-h period of ambulatory blood pressure on a non-work day for participant. Work schedules over a 4-week period will be collected and participants identified as traditional or non-traditional workers.~Subjects will begin the stay in the research unit in the evening and will remain for about 16-20 hr. Saliva samples will be taken every 30 min from admission until bedtime. Bedtime with polysomnography will be from 11:00pm to 7:00am. Questionnaires will be administered; height, weight and waist/hip circumference and bioimpedance measurement; standard 3-h oral glucose tolerance test and blood tests (CBC, electrolytes, renal, liver and thyroid function , hemoglobin A1c, SHBG levels). For individuals with diabetes only fasting blood samples will be taken.
Study: NCT03376555

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Heating (LH)
Description: Probe 1. Lactated Ringer's only (control) Probe 2. Lactated Ringer's + Ascorbate Probe 3. Lactated Ringer's + Tempol Probe 4. Lactated Ringer's + Apocynin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local Heating (LH)
Description: Probe 1. Lactated Ringer's only (control) Probe 2. Lactated Ringer's + Ascorbate Probe 3. Lactated Ringer's + Tempol Probe 4. Lactated Ringer's + Apocynin
Study: NCT02214849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LATCH Intervention
Study: NCT01993979

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy

Intervention type: OTHER
Group type: OTHER
Intervention: Surveillance
Description: Patients will be closely monitored for early signs of recurrence, for which they will receive treatment as decided in discussion between the clinician and patient. This may include chemotherapy.
Study: NCT04012749

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advance directive
Description: Patient receives a health system-specific advance directive along with a message crafted with input from a broad group of stakeholders at the clinical sites and external advisors. Messaging introduces advance care planning, the purpose of the advance directive and contains instructions for completing it and turning it in, as well as a prompt to discuss the document with the patient's primary care physician.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advance directive
Description: Patient receives a health system-specific advance directive along with a message crafted with input from a broad group of stakeholders at the clinical sites and external advisors. Messaging introduces advance care planning, the purpose of the advance directive and contains instructions for completing it and turning it in, as well as a prompt to discuss the document with the patient's primary care physician.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Advance directive
Description: Patient receives a health system-specific advance directive along with a message crafted with input from a broad group of stakeholders at the clinical sites and external advisors. Messaging introduces advance care planning, the purpose of the advance directive and contains instructions for completing it and turning it in, as well as a prompt to discuss the document with the patient's primary care physician.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prepare
Description: Patient invited to use the Prepare For Your Care website (www.prepareforyourcare.org) that will introduce and facilitate advance care planning and guide completion of an advance directive.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prepare
Description: Patient invited to use the Prepare For Your Care website (www.prepareforyourcare.org) that will introduce and facilitate advance care planning and guide completion of an advance directive.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Facilitator
Description: Facilitator engages patient to activate advance care planning and to carry out navigation and facilitation aspects of advance care planning. Facilitator can tee up advance care planning activities with the primary care physician.
Study: NCT02353741

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EGFR-TKIs
Description: Beginning on day 2 of treatment, receive oral erlotinib 150mg per day.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: thoracic radiotherapy
Description: From the beginning of EGFR-TKIs, within 2 weeks, receive concurrent thoracic radiotherapy, pGTV54～60Gy/27～30f/5.5～6w.
Study: NCT02240706

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: At Discretion of the Investigator (Transfusions)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care
Description: At Discretion of the Investigator (Transfusions)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836858
Description: Monotherapy with BI 836858
Study: NCT03032744

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asthma Assessment & Management
Description: Asthma Assessment \& Management based on NAEPP-EPR3 guidelines

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Asthma Assessment & Management
Description: Asthma Assessment \& Management based on NAEPP-EPR3 guidelines

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Asthma Education
Description: Asthma education on medications

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Asthma Education
Description: Asthma education on medications

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Controller medication at school
Description: Students will receive the morning dose of their daily preventive asthma medication at school on school days.
Study: NCT04313946

Intervention type: DIAGNOSTIC_TEST
Intervention: Scanning Chest X-rays and performing AI algorithms on images
Description: Chest X-Rays; AI CNNs; Results
Study: NCT03832387

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive mechanical ventilation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continuous positive airway pressure

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Venturi mask

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Reservoir mask
Study: NCT02485392

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Da Vinci Single Site Robot-Assisted Cholecystectomy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Single Incision Laparoscopic Cholecystectomy
Study: NCT03406026

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Balance System Protocol Stroke
Description: This arm perform 5 sessions of 1 hour a week. All sessions will be performed by the same physiotherapist. One session consists of 45 minutes of regular physiotherapy and 15 minutes in which exercises will be carried out focused on the balance systems, following the program that is detailed below.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Stroke
Description: This arm perform 5 sessions of 1 hour a week. All sessions will be performed by the same physiotherapist. The control group will perform, during the 60 minutes that the session lasts, the usual physiotherapy treatment.
Study: NCT03845530

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood Test
Description: Blood test taken and sent for laboratory analysis

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Blood Test
Description: Blood test taken and sent for laboratory analysis
Study: NCT00435643

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: nasal continuous positive airway pressure
Description: After an average interval of three months, 10 patients with severe OSAS (AHI of more than 30 events per hour of sleep) treated with a mean nCPAP pressure of 11.2 ± 0.7 cm of H2O were reassessed and all mentioned measurements above were repeated
Study: NCT00478036

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acular LS
Description: Details covered in arm description

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pred Forte
Description: Details covered in arm description

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Refresh Tears
Description: Placebo
Study: NCT02478684

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 30 Seconds of placental blood transfusion
Description: By delaying clamping of the cord blood for 30 seconds, blood will be allowed to move from the placenta to the premature infant

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 60 Seconds of placental blood transfusion
Description: By delaying clamping of the cord blood for 60 seconds, blood will be allowed to move from the placenta to the premature infant
Study: NCT02191748

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Needling
Description: Needling is a procedure in which a needle is inserted into normally pigmented skin on the rim of a vitiligo patch and then is pushed into the center of the patch, theoretically moving healthy, pigmented skin cells into the vitiligo patch.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Needling
Description: Needling is a procedure in which a needle is inserted into normally pigmented skin on the rim of a vitiligo patch and then is pushed into the center of the patch, theoretically moving healthy, pigmented skin cells into the vitiligo patch.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triamcinolone
Description: During the process of needling, the needle will be attached to a syringe filled with a steroid, which is then injected into the patch, enabling delivery of the steroid directly to the affected area
Study: NCT01360203

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured Telephone / Remote Outpatient Monitoring
Description: During their hospitalization, patients will receive education on their condition and will be taught to use a wireless remote monitoring device that they will use from home on a daily basis for six months following hospital discharge. Patients will receive structured telephone phone calls from a centralized call center nurse at least once a week for the first month post-discharge, and monthly for the remainder of the six month study period. Patients may receive additional calls depending upon the information gathered during the scheduled call center phone calls and/or their health status as ascertained by the data (weight, heart rate, blood pressure, answers to general health and heart failure-related questions) transmitted daily by the wireless remote monitoring device.
Study: NCT00187590

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Case manager phone call after an ER visit
Study: NCT03862456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Azithromycin
Description: azithromycin (500 mg/24h/3 days)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: metronidazole (500 mg/8h/7 days)
Study: NCT02624648

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Female Sexual Function Index (FSFI)
Description: The Female Sexual Function Index (FSFI) Questionnaire to evaluate the sexual function

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: The Female Sexual Function Index (FSFI)
Description: The Female Sexual Function Index (FSFI) Questionnaire to evaluate the sexual function

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Female Intervention Efficacy Index (FIEI)
Description: The Female Intervention Efficacy Index Questionnaire (FIEI) to evaluate the sexual function

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: The Female Intervention Efficacy Index (FIEI)
Description: The Female Intervention Efficacy Index Questionnaire (FIEI) to evaluate the sexual function

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Beck Depression Inventory II
Description: The Beck Depression Inventory II will be used to evaluate or ward off depression

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: The Beck Depression Inventory II
Description: The Beck Depression Inventory II will be used to evaluate or ward off depression

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lepidium Meyenii Walp
Description: They will receive a capsule of Lepidium Meyenii Walp twice a day for 120 days
Study: NCT03819907

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Audiovisual Guided Relaxation
Description: Five-minute guided relaxation delivered via a computer screen and speakers
Study: NCT02624648

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: They will receive a capsule of Placebo twice a day for 120 days
Study: NCT01151072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Each subject was randomly allocated to five single dose administrations of NN1250 subcutaneously (under the skin) in the thigh, the abdomen (stomach) and the deltoid (shoulder), intramuscularly (into the muscle) in the thigh and intravenously (into the vein), respectively, on five separate dosing visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Each subject was randomly allocated to five single dose administrations of NN1250 subcutaneously (under the skin) in the thigh, the abdomen (stomach) and the deltoid (shoulder), intramuscularly (into the muscle) in the thigh and intravenously (into the vein), respectively, on five separate dosing visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Each subject was randomly allocated to five single dose administrations of NN1250 subcutaneously (under the skin) in the thigh, the abdomen (stomach) and the deltoid (shoulder), intramuscularly (into the muscle) in the thigh and intravenously (into the vein), respectively, on five separate dosing visits.
Study: NCT03819907

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Virtual Reality Guided Relaxation
Description: Five-minute guided relaxation delivered via a Samsung Galaxy 7s and the Samsung adaptable VR headset.
Study: NCT02473692

Intervention type: OTHER
Intervention: Online Migraine Treatment Optimization
Description: The educational videos entail a young woman (i.e., an actress) describing her experiences in managing her headaches. The informational content of the videos is organized into 7 content areas that present a wealth of information in an entertaining way:~1. Introduction to the series~2. Getting to know migraine~3. Making the most of your medical care~4. Partnering with your doctor~5. Best use of migraine medication~6. Keeping tabs on your migraine~7. Take home message (summary)
Study: NCT04575597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
Study: NCT01151072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Each subject was randomly allocated to five single dose administrations of NN1250 subcutaneously (under the skin) in the thigh, the abdomen (stomach) and the deltoid (shoulder), intramuscularly (into the muscle) in the thigh and intravenously (into the vein), respectively, on five separate dosing visits.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin degludec
Description: Each subject was randomly allocated to five single dose administrations of NN1250 subcutaneously (under the skin) in the thigh, the abdomen (stomach) and the deltoid (shoulder), intramuscularly (into the muscle) in the thigh and intravenously (into the vein), respectively, on five separate dosing visits.
Study: NCT00780403

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: desloratadine RediTabs, 1 tablet (2.5 mg),oral administration, single day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Desloratadine
Description: desloratadine RediTabs, 1 tablet (2.5 mg),oral administration, single day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyrtec® (cetirizine)
Description: Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyrtec® (cetirizine)
Description: Zyrtec® (cetirizine) Chewable Tablets, 1 tablet (5 mg), oral administration, single day
Study: NCT04575597

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Molnupiravir
Description: Molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
Study: NCT02553954

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collection of healthy skin tissue
Description: Collection of two samples of healthy skin tissue, without disfigurement, during an intervention under general anesthesia for the treatment of a benign or malignant tumor.
Study: NCT00105365

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Shoe insert
Description: Subjects with knee OA underwent gait analysis and knee pain and function assessment at baseline while wearing walking shoes and after four weeks of wearing walking shoes with lateral-wedged insoles.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: walking shoes
Description: walking shoes
Study: NCT04272138

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Calm Meditation
Description: The intervention will run for 4-weeks. Participants will complete the 30 day, How to Meditate meditation series that provides daily 10-minute meditations. Throughout the intervention, participants will be sent reminder emails via REDCap to participate in their assigned practice sessions participants and will complete online weekly participation logs via REDCap. Additionally, they will answer one, multiple-choice ecological momentary assessment question, randomly, 3x per day via test message assessing how one currently feels. Participants will complete baseline and post-intervention measures of the Perceived Stress Scale, Hospital Anxiety and Depression Scale, Mindfulness Attention Awareness Scale, International Physical Activity Questionnaire, Salzberg Stress Eating Scale, Brief Cope, and Brief Resilience Scale. Following these measures, participants will be asked to complete a satisfaction questionnaire (week 5) and have the opportunity to volunteer for a short phone interview.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational Podcast Control
Description: The intervention will run for 4-weeks. Control group participants will listen to daily 10-minute health education podcasts. Throughout the intervention, participants will be sent reminder emails via REDCap to participate in their assigned practice sessions and participants will complete online weekly participation logs via REDCap. Additionally, they will answer one, multiple-choice EMA (ecological momentary assessment) question, randomly, 3x per day via test message assessing how one currently feels. Participants will complete baseline and post-intervention measures of the Perceived Stress Scale, Hospital Anxiety and Depression Scale, Mindfulness Attention Awareness Scale, International Physical Activity Questionnaire, Salzberg Stress Eating Scale, Brief Cope, and Brief Resilience Scale. Following these measures, participants will be asked to complete a satisfaction questionnaire (week 5) and have the opportunity to volunteer for a short phone interview.
Study: NCT03785275

Intervention type: RADIATION
Intervention: gallium-68-exendin PET/CT
Description: PET/CT scan after injection with gallium-68-exendin

Intervention type: RADIATION
Intervention: gallium-68-exendin PET/CT
Description: PET/CT scan after injection with gallium-68-exendin
Study: NCT04142879

Intervention type: DEVICE
Intervention: Viz Device Software
Description: Viz uses artificial intelligence to automatically detect, triage and notify stroke specialists of suspected large vessel occlusion (LVOs) and computed tomography angiogram (CTA) imaging. Viz includes functionality to automatically process computed tomography perfusion (CTP) images. Additionally, Viz includes a mobile non-diagnostic image viewer and HIPAA-compliant secure messaging.

Intervention type: DEVICE
Intervention: Viz Device Software
Description: Viz uses artificial intelligence to automatically detect, triage and notify stroke specialists of suspected large vessel occlusion (LVOs) and computed tomography angiogram (CTA) imaging. Viz includes functionality to automatically process computed tomography perfusion (CTP) images. Additionally, Viz includes a mobile non-diagnostic image viewer and HIPAA-compliant secure messaging.
Study: NCT00429247

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab,first administration at the dose of 8mg/Kg IV, subsequent administrations at the dose of 6mg/Kg IV,every 3 weeks for 6 cycles
Study: NCT03315052

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Budesonide
Description: Oral steroid with high first-pass metabolism in liver

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tacrolimus（FK506）
Description: Calcineurin immunosuppressant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus（FK506）
Description: Calcineurin immunosuppressant

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Immunosupressant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: Immunosupressant

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Immunosuppresant